I noticed I have 27 boardmarks, why are you bm me...... I am a newb!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am keeping an eye because according to the chart .17 is the 200MA....
again some light volume with shares being added.
Looks Great Georgie :)
hahahaha
I was taking a look at level 2 and saw a quick 100K at .16 at bid for about 2-3 seconds. Did you happen to see it? I was trying to Screenshot and it was gone
some EOD buying happening.
there has been quite a few bought from management checking the most form 4 filings.
116300 trade at 16:00:51 = 3,362,233
Did you just see the volume? I am seeing 383K shares traded?
some back and forth following with selling... earnings tomorrow. Going to wait it through.
There has been some insider buying from what I see as well. Suprise at the lack of chatter on this.
Even through for profit institutions have been taking quite a hit, its good to see this company offer no debt plan.
.152 x .1599
Last buy was 10K shares at .158
Seems like there will need to be some churn at .17 at level 2
Aspen University Announces New Student Enrollments Rise 110% YoY
Nov 04, 2015
OTC Disclosure & News Service
-
Preliminary Fiscal Second Quarter Revenue Increases Over 54% YoY
Aspen’s Degree-Seeking Student Body Hits 4,000; Forecasting 5,000 Students by Fiscal Year End, April 30, 2016
NEW YORK, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (OTCQB:ASPU), a nationally accredited online post-secondary education company (Aspen University), today announced a quarterly enrollment record with 557 new student enrollments in fiscal second quarter (ending October 31, 2015), as compared to 265 new student enrollments in the prior year, an increase of 110%.
New Student Enrollments:
Fiscal Second Quarter End October 31, 2015 557
Fiscal First Quarter End July 31, 2015 410
Fiscal Fourth Quarter End April 30, 2015 444
Fiscal Third Quarter End January 31, 2015 315
Fiscal Second Quarter End October 31, 2014 265
Aspen’s School of Nursing is responsible for the lion’s share of the new student enrollment and overall student body growth. Specifically, Aspen’s School of Nursing is now on pace to grow on an annualized basis by 1,500 Nursing students – net* (or 125/month). Aspen’s BSN program accounts for 72% of that growth, as that program is on pace to increase on an annualized basis by 1,080 students – net* (or 90/month).
As of October 31, 2015, Aspen’s School of Nursing accounts for 48% of the degree-seeking student body, or 1,935 Nursing students, of the 4,015 total degree-seeking student body. The School of Nursing is forecasted to represent the majority of Aspen’s degree-seeking students by the end of this fiscal year (April 30, 2016).
“Aspen University devised a business model just over 18 months ago – offering a debt-free solution through monthly payment plans – that was designed to end the assumption that students have historically made that they must incur overwhelming debt to obtain a college degree,” said Aspen Group Chairman and CEO Michael Mathews. “RNs in particular, from all over the United States, have adopted the debtless education solution at Aspen, and we are excited to offer this opportunity to thousands more in the coming years,” continued Mathews.
Preliminary Second Quarter FY’16 Revenue Results:
Based on preliminary review of the second quarter ended October 31, 2015, the company expects second quarter revenue growth to accelerate to over 54% year-over-year, reporting revenue of approximately $1,875,000. Second quarter results of operations will be announced following the market close on December 2, 2015.
Forecasted Student Body Growth:
Aspen University expects its total degree-seeking student body to continue its rapid growth and reach approximately 5,000 students by April 30, 2016, a sharp increase from 4,015 as of October 31, 2015. Therefore, the university is now on pace to increase its student body by 2,000 students on an annualized basis versus the previous pace of 1,200 students earlier this fiscal year.
About Aspen Group, Inc.
Aspen Group, Inc. is an online postsecondary education company. Aspen University’s mission is to offer any motivated college-worthy student the opportunity to receive a high quality, responsibly priced distance-learning education for the purpose of achieving sustainable economic and social benefits for themselves and their families. Aspen is dedicated to providing the highest quality education experiences taught by top-tier faculty - 60% of our adjunct faculty hold doctoral degrees. To learn more about Aspen, visit www.aspen.edu.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including projections, trends and continued growth in our new student enrollments and revenue the Company expects to report for the second quarter.
The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include student attrition beyond what the Company has historically experienced, the trend in of increased new student enrollment does not continue and unanticipated results from our auditors’ review of the second quarter operations. Further information on our risk factors is contained in our filings with the SEC, including the Prospectus dated October 14, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
*Student body growth – net – takes into account graduations and student attrition.
Media Contact:
Aspen Group, Inc.
Michael Mathews, CEO
914-906-9159
watching
Still?
perhaps the opportunity to grab more. Lets see how it plays out.
Some consolidation, seems like support at 8.20
Getting close to the 29 break.
3rd Quarter Earnings coming 11/5/15. Hoping to see it propel the stock back over 30
holding steady
28.38 x 28.40
28.38 x 28.40
looking solid over 28.... hoping to see 30's shortly. 4Q in Temp Staffing should be strong.
you said slow and steady and that sounds right.
One step at a time, talk of pennies is premature.
What I like from level 2 perspective is that shares are being absorbed by additional buys holding out for a higher pps, creating a new base line prior to the next possible leg.
Again you have folks absorbing shares at .0009 ready for higher levels. Quite a few shares have been picked up at .0009-.001 levels
3.5 million helping to thin out .001.
3mm on bid and 3 on ask
2.10 million and 1.88 million on ask
Looking at level two throughout the day the dump you speak of seemed to be shares being acquired with folks on the bid.
Grabbed a bit on from weak hands.
17K buy at 8.23.....
Honestly 1-2% gains per day is just fine with me.
8.10 x 8.20 bid is building at 8.10.
SC 13G 1 v422842_sc13g.htm SC 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.__)*
Strongbridge Biopharma plc
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
G85347105
(CUSIP Number)
October 16, 2015
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. G85347105 13G
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
RA Capital Management, LLC
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Citizenship or Place of Organization Massachusetts
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With 5. Sole Voting Power 0 shares
6. Shared Voting Power 2,690,702 shares
7. Sole Dispositive Power 0 shares
8. Shared Dispositive Power 2,690,702 shares
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,690,702 shares
10.
Check if the Aggregate Amount in Row (9) Excludes ¨
Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
12.7%
12.
Type of Reporting Person (See Instructions)
IA
CUSIP No. G85347105 13G
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Peter Kolchinsky
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Citizenship or Place of Organization United States
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With 5. Sole Voting Power 0 shares
6. Shared Voting Power 2,690,702 shares
7. Sole Dispositive Power 0 shares
8. Shared Dispositive Power 2,690,702 shares
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,690,702 shares
10.
Check if the Aggregate Amount in Row (9) Excludes ¨
Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
12.7%
12.
Type of Reporting Person (See Instructions)
IN
CUSIP No. G85347105 13G
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
RA Capital Healthcare Fund, L.P.
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3. SEC Use Only
4. Citizenship or Place of Organization Delaware
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With 5. Sole Voting Power 0 shares
6. Shared Voting Power 2,202,140 shares
7. Sole Dispositive Power 0 shares
8. Shared Dispositive Power 2,202,140 shares
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
2,202,140 shares
10.
Check if the Aggregate Amount in Row (9) Excludes ¨
Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
10.4%
12.
Type of Reporting Person (See Instructions)
PN (Limited Partnership)
CUSIP No. G85347105
Item 1.
(a) Name of Issuer: Strongbridge Biopharma plc (the “Issuer”).
(b) Address of the Issuer’s Principal Executive Offices: 900 Northbrook Drive, Suite 200, Trevose, PA 19053.
Item 2.
(a) Name of Person Filing: This joint statement on Schedule 13G is being filed by Peter Kolchinsky, RA Capital Management, LLC (“Capital”), and RA Capital Healthcare Fund, L.P. (the “Fund”). Mr. Kolchinsky, Capital and the Fund are collectively referred to herein as the “Reporting Persons.”
(b) Address of Principal Business Office: The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20 Park Plaza, Suite 1200, Boston, MA 02116.
(c) Citizenship: Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. Mr. Kolchinsky is a United States citizen.
(d) Title and Class of Securities: Common stock (“Common Stock”)
(e) CUSIP Number: G85347105
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4. Ownership:
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a)
Amount Beneficially Owned:**
RA Capital Management, LLC – 2,690,702 shares
Peter Kolchinsky – 2,690,702 shares
RA Capital Healthcare Fund, L.P. – 2,202,140 shares
(b) Percent of Class:**
RA Capital Management, LLC – 12.7%
Peter Kolchinsky – 12.7%
RA Capital Healthcare Fund, L.P. – 10.4%
CUSIP No. G85347105
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote **
RA Capital Management, LLC - 0 shares
Peter Kolchinsky - 0 shares
RA Capital Healthcare Fund, L.P. - 0 shares
(ii) shared power to vote or to direct the vote**
RA Capital Management, LLC – 2,690,702 shares
Peter Kolchinsky – 2,690,702 shares
RA Capital Healthcare Fund, L.P. – 2,202,140 shares
(iii) sole power to dispose or to direct the disposition of**
RA Capital Management, LLC - 0 shares
Peter Kolchinsky - 0 shares
RA Capital Healthcare Fund, L.P. - 0 shares
(iv) shared power to dispose or to direct the disposition of**
RA Capital Management, LLC – 2,690,702 shares
Peter Kolchinsky – 2,690,702 shares
RA Capital Healthcare Fund, L.P. – 2,202,140 shares
** RA Capital Management, LLC (“Capital”) is the general partner of RA Capital Healthcare Fund, L.P. (the “Fund”) and serves as investment adviser for a separately managed account (the “Account”). Peter Kolchinsky is the manager of Capital. Mr. Kolchinsky, Capital and the Fund are referred to herein collectively as the “Reporting Persons.” As the investment adviser to the Fund and the Account, Capital may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer owned by the Fund or the Account. As the manager of Capital, Mr. Kolchinsky may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Capital. Capital is a registered investment adviser within the meaning of Rule 13d-1(b)(1)(ii)(E) and Rule 16a-1(a)(v), and Mr. Kolchinsky is a parent or control person of Capital within the meaning of Rule 13d-1(b)(1)(ii)(G) and Rule 16a-1(a)(1)(vii). Capital and Mr. Kolchinsky disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and neither the filing of the Statement nor the filing of this Amendment shall not be deemed an admission that either Capital or Mr. Kolchinsky is or was the beneficial owner of such securities for any other purpose.
Item 5. Ownership of Five Percent or Less of a Class:
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not applicable.
CUSIP No. G85347105
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:
Not applicable.
Item 8. Identification and Classification of Members of the Group:
Not applicable.
Item 9. Notice of Dissolution of Group:
Not applicable.
Item 10. Certification:
By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP No. G85347105
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DATE: October 26, 2015
RA CAPITAL MANAGEMENT, LLC
By: /s/ Rajeev Shah
-------------------------------------------------
Rajeev Shah
Authorized Signatory
PETER KOLCHINSKY
/s/ Peter Kolchinsky
-------------------------------------------------
RA CAPITAL HEALTHCARE FUND, L.P.
By: RA Capital Management, LLC
Its: General Partner
By: /s/ Rajeev Shah
-------------------------------------------------
Rajeev Shah
Authorized Signatory
Exhibit 1
JOINT FILING AGREEMENT
This Joint Filing Agreement, dated as of October 26, 2015, is by and among RA Capital Management, LLC, Peter Kolchinsky, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Shares, par value $0.01 per share of Strongbridge Biopharma plc beneficially owned by them from time to time.
Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.
This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.
Executed and delivered as of the date first above written.
http://www.sec.gov/Archives/edgar/data/1346824/000114420415060785/v422842_sc13g.htm
RA CAPITAL MANAGEMENT, LLC
By: /s/ Rajeev Shah
-------------------------------------------------
Rajeev Shah
Authorized Signatory
PETER KOLCHINSKY
/s/ Peter Kolchinsky
-------------------------------------------------
RA CAPITAL HEALTHCARE FUND, L.P.
By: RA Capital Management, LLC
Its: General Partner
By: /s/ Rajeev Shah
-------------------------------------------------
Rajeev Shah
Authorized Signatory
HI yahoo4 do you know when he did this?
hoping to see a close above $8.00
The last 5 minutes had some decent buying.
Over 250K in volume seems decently liquid
Some info:
http://www.strongbridgebio.com/
Strongbridge Biopharma is a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases.
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Strongbridge Biopharma’s rare disease franchise includes the following product candidates:
COR-003 (levoketoconazole), a cortisol synthesis inhibitor, is being evaluated in a Phase 3 pivotal trial for the treatment of endogenous Cushing’s syndrome. Endogenous Cushing’s syndrome is a rare endocrine disorder characterized by sustained elevated cortisol levels that most commonly result from a benign tumor of the pituitary gland. COR-003 has been granted orphan drug designation by the U.S. Food and Drug Administration, or the FDA, and the European Medicines Agency, or the EMA. The Company is developing COR-003, a single enantiomer of ketoconazole, as a new chemical entity, or NCE, under the FDA 505(b)(2) regulatory pathway, and intends to reference the FDA’s prior conclusions of safety and effectiveness for ketoconazole.
COR-004, a second-generation antisense oligonucleotide, is in Phase 2 clinical development for the treatment of acromegaly. Acromegaly is a rare endocrine disorder that most commonly results from a benign tumor of the pituitary gland, leading to excess production of growth hormone, or GH, and insulin-like growth factor 1, or IGF-1, a key regulator of growth and metabolism. COR-004 has a novel mechanism of action targeting human GH receptor messenger RNA, or GHR mRNA, a molecule that is necessary for the synthesis of GHR protein. Currently, somatostatin analogs, or SSAs, are the most commonly used drug therapy for the treatment of patients with acromegaly. Up to one-half of treated patients do not adequately respond to SSAs and need alternative or adjunctive drug therapies. The novel mechanism of action of COR-004 may result in a differentiated safety and efficacy profile as compared to pegvisomant, the most common drug therapy used as an alternative to or in combination with SSAs.
COR-005, a novel somatostatin analog (SSA), is in Phase 2 clinical development for the treatment of acromegaly. Based on the differentiated activation pattern of COR -005 to somatostatin receptor subtypes, or SSTRs, and preclinical and clinical data COR -005 may offer an improved efficacy and safety profile relative to existing drug therapies for acromegaly. COR -005 has been granted orphan drug designation by the FDA and the EMA.
7.70 x 7.75 seems like the spread is finally coming together as there were larger gaps this morning, I am hoping to see some churning through 7's and a base line at 8.50.
Grabbed some this morning.
Hi Roy any particular interest here?
Keeping an eye with you Roy. Long time no speak. Hope you have been treated well.
esidney you still on this?